Clinical Trials Logo

Filter by:
NCT ID: NCT05232409 Recruiting - Clinical trials for Metastatic Solid Tumor

Determine Safety & Recommended Phase 2 Dosing of Zeaxanthin Alone or in Combination w/Pembrolizumab in Patients With Metastatic Cancer

Start date: April 17, 2022
Phase: Phase 1
Study type: Interventional

The purpose of the research is to determine the highest dose of an oral compound called zeaxanthin that can be safely taken each day in patients with advanced cancer, the toxicity profile of zeaxanthin, and the dose of zeaxanthin to use in future cancer clinical trials.

NCT ID: NCT05234957 Recruiting - Clinical trials for Intermittent Exotropia

Symmetric vs Asymmetric BLR Recession in Management of Basic IXT With Ocular Dominance

Start date: April 17, 2022
Phase: N/A
Study type: Interventional

The study aims to investigate ocular motor and sensory outcomes of two different strategies of lateral rectus recession; symmetric and asymmetric, in management of basic type intermittent exotropia with ocular dominance.

NCT ID: NCT05306080 Recruiting - HLH Clinical Trials

Tadekinig Alfa (IL-18BP) Rescue Therapy for CAR T Cell Related Cytokine Release Syndrome (CRS) and HLH-like Syndrome

Start date: April 17, 2022
Phase: Early Phase 1
Study type: Interventional

This is a pilot, open-label study to assess the safety and feasibility of using investigational drug(s) as rescue therapies for CAR T cell related CRS and HLH-like syndrome (CRHLS).

NCT ID: NCT05341362 Recruiting - Clinical trials for Supine Hypotensive Syndrome

Hemodynamic Management in Women With SHS

Start date: April 17, 2022
Phase: N/A
Study type: Interventional

Supine hypotensive syndrome often occurs following spinal anesthesia for cesarean delivery.In our study we base the regulation and drug administration both on the regular monitor and on a novel monitor which reflects upon the hemodynamic changes. Our aim is to observe whether the outcome of SHS patients with anesthesia management based on hemodynamic figures differs from those based on experience.

NCT ID: NCT05342792 Recruiting - Clinical trials for Nasopharyngeal Carcinoma

Metronomic Capecitabine With or Without PD-1 Antibody as Adjuvant Therapy in High-risk Nasopharyngeal Carcinoma

Start date: April 17, 2022
Phase: Phase 3
Study type: Interventional

This trial is aimed to investigate whether additional adjuvant PD-1 antibody treatment could improve survival in high-risk nasopharyngeal carcinoma compared to metronomic capecitabine alone.

NCT ID: NCT05696977 Recruiting - Nephrotic Syndrome Clinical Trials

Effect of Obesity on Cyclosporine Blood Trough Level in Nephrotic Syndrome Patients

Start date: April 17, 2022
Phase: Phase 4
Study type: Interventional

This study aims to assess the effect of obesity on therapeutic response and safety of cyclosporine trough level in nephrotic syndrome patients and calculating a suitable weight-based dose.

NCT ID: NCT05707221 Recruiting - Oral Disease Clinical Trials

Effect of Different Cleaning Regimes on Biofilm Formation of Acrylic Based Removable Orthodontic Appliance

Start date: April 17, 2022
Phase: N/A
Study type: Interventional

This study is to evaluate the effects of different cleaning regimes i.e. chemical and mechanical on biofilm formation of an acrylic based removable orthodontic appliance and to find out if surface modification i.e. polished acrylic fitting surface, have an impact on cleaning the biofilm formation.

NCT ID: NCT03966651 Recruiting - Neuroblastoma Clinical Trials

A Clinical Study Evaluating the Safety of Peptide Receptor Radionuclide Therapy (PRRT) With 177Lu-DOTA0-Tyr3-Octreotate in Children With Refractory or Recurrent Neuroblastoma Expressing Somatostatin Receptors.

NEUROBLU 02
Start date: April 17, 2023
Phase: Phase 1
Study type: Interventional

This study is a multicenter, open label phase I dose escalation trial designed to define the Maximum Tolerated Dose (MTD) of 177Lu-DOTATATE in children with refractory or recurrent neuroblastoma. 177Lu-DOTATATE will be delivered intravenously for 2 cycles, 6 weeks apart. The duration of study participation of each patient will be 5 months.

NCT ID: NCT04124120 Recruiting - Clinical trials for Coronary Artery Disease

Comparison of the Outcomes of Single vs Multiple Arterial Grafts in Women

ROMA:Women
Start date: April 17, 2023
Phase: N/A
Study type: Interventional

The central hypothesis of ROMA:Women is that the use of multiple arterial grafting (MAG) will improve clinical outcomes and quality of life (QOL) compared to single arterial grfating (SAG). The specific aims of ROMA:Women are: Aim 1: Determine the impact of MAG vs SAG on major adverse cardiac and cerebrovascular events in women undergoing coronary artery bypass grfating (CABG). The investigators will compare major adverse cardiac and cerebrovascular events (death, stroke, non-procedural myocardial infarction, repeat revascularization, and hospital readmission for acute coronary syndrome or heart failure) in a cohort of 2,000 women randomized 1:1 to MAG or SAG (690 from the parent ROMA trial + 1,310 from ROMA:Women). Differences by important clinical and surgical subgroups (patients younger or older than 70 years, diabetics, racial and ethnic minorities, on vs off pump CABG, type of arterial grafts used) will also be evaluated. The women enrolled in the ongoing ROMA trial (anticipated to be approximately 690) will be included in ROMA:Women, increasing efficiency and reducing enrollment time. Hypothesis 1.0. MAG will reduce the incidence of major adverse cardiac and cerebrovascular events. Hypothesis 1.1. The improvement with MAG will be consistent across key subgroups. Aim 2: Determine the impact of MAG vs SAG on generic and disease-specific QOL, physical and mental health symptoms in women undergoing CABG. The investigators will compare generic (SF-12, EQ-5D) and disease-specific (Seattle Angina Questionnaire) QOL and physical and mental health symptoms (PROMIS-29) in a sub-cohort of 500 women randomized 1:1 to MAG or SAG (including those enrolled in ROMA:QOL). Differences by important subgroups (as defined above) will also be evaluated. Hypothesis 2.0. MAG will improve generic and disease-specific QOL compared to SAG. Hypothesis 2.1. MAG will improve physical and mental health symptoms compared to SAG. Hypothesis 2.2. The improvement with MAG will be consistent across key subgroups.

NCT ID: NCT05294263 Recruiting - Clinical trials for Tobacco Use Disorder

Varenicline for the Treatment of Cannabis and Tobacco Use Disorders in Veterans

Vet Cat
Start date: April 17, 2023
Phase: Phase 2
Study type: Interventional

After initial eligibility screening, Veterans who use both cannabis and tobacco will be randomly assigned to receive either varenicline (Chantix) or placebo for 12 weeks. Participants will attend weekly visits, in person or remotely, to provide breath and urine samples for testing, fill out questionnaires, and meet with study staff about medication compliance.